<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03815890</url>
  </required_header>
  <id_info>
    <org_study_id>M18BEL</org_study_id>
    <nct_id>NCT03815890</nct_id>
  </id_info>
  <brief_title>Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO</brief_title>
  <acronym>BELLINI</acronym>
  <official_title>Pre-operative Phase II Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether short-term pre-operative nivolumab either as monotherapy or in&#xD;
      combination with low dose doxorubicin or novel IO combinations can induce immune activation&#xD;
      in early BC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to test the activity of nivolumab monotherapy in primary breast tumors&#xD;
      in a pre-operative window of opportunity trial. As the data of the investigators generated in&#xD;
      the TONIC trial (metastatic TNBC) indicate that low dose doxorubicin may 'prime' the tumor&#xD;
      microenvironment (TME) resulting in higher response rates on nivolumab, in addition, cohorts&#xD;
      for treatment with nivolumab plus low dose doxorubicin will be opened. Given the emerging&#xD;
      data on other immunomodulatory strategies, this platform study allows opening additional&#xD;
      cohorts for promising novel immune-oncology (IO) drugs for which a strong efficacy signal has&#xD;
      been seen without drug safety issues. The investigators will study the TME and systemic host&#xD;
      factors with specific emphasis on immunosuppressive processes that can potentially be&#xD;
      targeted by novel IO agents to further optimize BC immunotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">January 7, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 7, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Separate cohorts will be opened in this trial. LumB and TNBC tumors will be divided in separate cohorts.More cohorts, e.g. combining nivolumab and novel IO, can open after the start of this trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune activation after pre-operative nivolumab</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>measuring the tumor-associated CD8 and expression of genes induced by IFNy after pre-operative immunotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events according to NCI Common Toxicity Criteria version 5.0</measure>
    <time_frame>up to 3 weeks after surgery, an average of 6 months</time_frame>
    <description>Adverse events in all regimens will be graded according to NCI Common Toxicity Criteria version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response rate</measure>
    <time_frame>At 4 weeks</time_frame>
    <description>The percentage of patients having a complete response, partial response or stable disease per cohort assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>up to 3 weeks after surgery, an average of 6 months</time_frame>
    <description>The percentage of patients having a complete response or residual cancer burden per cohort</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1A; LumB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B; TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A; LUMB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab and ipilimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B; TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab and ipilimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3B; TNBC, High TIL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab and ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>2 courses 240 mg flat dose</description>
    <arm_group_label>1A; LumB</arm_group_label>
    <arm_group_label>1B; TNBC</arm_group_label>
    <arm_group_label>2A; LUMB</arm_group_label>
    <arm_group_label>2B; TNBC</arm_group_label>
    <arm_group_label>3B; TNBC, High TIL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>single dose ipilimumab (1mg/kg) at day 1</description>
    <arm_group_label>2A; LUMB</arm_group_label>
    <arm_group_label>2B; TNBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>two courses ipilimumab (1mg/kg) at day 1 and 21</description>
    <arm_group_label>3B; TNBC, High TIL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  18 years or older at moment of inclusion;&#xD;
&#xD;
          -  Female gender;&#xD;
&#xD;
          -  WHO performance status 0 or 1;&#xD;
&#xD;
          -  Resectable primary breast cancer stage I-III. Nodal status must be examined by&#xD;
             ultrasound, fine needle aspiration, sentinel node biopsy, or FDG-PET scan.&#xD;
&#xD;
          -  The tumors must be:&#xD;
&#xD;
               -  at least 10 mm (minimum cT1c) as determined by MRI&#xD;
&#xD;
               -  TNBC defined as ER&lt;10%, HER2-negative OR luminal B defined as ER≥10%,&#xD;
                  HER2-negative with either grade 3 or Ki67≥20%. HER2 negative is defined as an IHC&#xD;
                  score of &lt;2 or 2+ with a negative ISH.&#xD;
&#xD;
               -  For cohort 3B: N0 status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  evidence or suspicion of metastatic disease. Evaluation of the presence of distant&#xD;
             metastases may include chest X-ray, liver ultrasound, isotope bone-scan, CT-scan of&#xD;
             chest and abdomen and/or FDG-PET scan, according to local procedures;&#xD;
&#xD;
          -  evidence of a concurrent contralateral or ipsilateral second primary infiltrating&#xD;
             breast cancer. Evaluation of the presence of a concurrent second primary breast cancer&#xD;
             may include mammography, breast ultrasound and/or MRI breast;&#xD;
&#xD;
          -  other malignancy except carcinoma in situ and basal-cell and squamous carcinoma of the&#xD;
             skin, unless the other malignancy was treated ≥5 years ago with curative intent&#xD;
             without the use of chemotherapy or radiotherapy&#xD;
&#xD;
          -  previous radiation therapy or chemotherapy;&#xD;
&#xD;
          -  prior treatment with checkpoint inhibitors (including anti- PD1, -PD-L1, -CTLA-4);&#xD;
&#xD;
          -  concurrent anti-cancer treatment, neoadjuvant therapy or another investigational drug;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Kok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M Kok, MD</last_name>
    <phone>3120512</phone>
    <phone_ext>9111</phone_ext>
    <email>m.kok@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>I Nederlof</last_name>
    <phone>3120512</phone>
    <phone_ext>9111</phone_ext>
    <email>i.nederlof@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Kok, MD</last_name>
      <email>m.kok@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>I Nederlof</last_name>
      <email>i.nederlof@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>M Kok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-operative</keyword>
  <keyword>triple negative and Luminal B</keyword>
  <keyword>resectable, stage I-III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>to be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

